We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Partnerships Developing Between IVD and IT Companies

By LabMedica International staff writers
Posted on 16 Jul 2013
Computers are helping doctors and laboratory technologists interpret results from complex tests that use DNA sequencing, proteomics, or mass spectroscopy. More...
Healthcare market research publisher, Kalorama Information (New York, NY, USA) reported that there is a noticeable increase in bioinformatic products, such as algorithmic support programs and image-reading software.

The volume and complexity of test data that is being produced is progressing too quickly for practicing physicians to stay current, and is driving new partnerships between computing giants and large in vitro diagnostics (IVD) firms, according to Kalorama's new market research report.

According to Kalorama Information, computer diagnostics could offer opportunity for clinical laboratory professionals to add value to clinicians in diagnosing diseases. Information Technology (IT) companies in collaboration with test vendors are developing computer software that complements the skills of human test interpretation. One important consideration is the increased pressure to reduce medical errors, including misdiagnosis. In addition, the ability to use clinical data to develop predictive algorithms adds significant value to lab test data. Important IVD companies that are expanding their bioinformatics platforms to develop new diagnostics include Qiagen, Roche, Illumina, and Life Technologies.

“It [is] a new dimension of precision compared to traditional diagnostics,” said Shara Rosen, analyst and author of the report. “The addition of informatics provides an added layer of precision by matching test data to disease progression and therapeutic outcomes.”

Shara Rosen said that in a bioinformatics-based test, results are treated as data points that then can be combined with multipatient information stored digitally in electronic medical records and other historical databases to create information that creates evidence-based precedence for treatment options.

Software specialists such as Ingenuity Systems (Redwood City, CA, USA) have partnered with molecular technology companies to develop algorithms, while pathology test companies such as Dako and Aperio have also joined imaging software innovators such as Definiens (Munich, Germany).

Kalorama's report indicates that a famous example is the use of IBM’s Watson supercomputer for cancer diagnostics. Doctors will be able to access Watson through a tablet or computer. Watson will compare a patient's medical records to what it has learned and make several recommendations (not decisions) in decreasing order of confidence. In the cancer program, the computer will consider what treatment is most likely to succeed. The system uses Watson's computational and natural language processing abilities as well as Memorial Sloan-Kettering Cancer Center (MSKCC) clinical expertise and cancer information to create an evidence-based decision support.

The report describes many more of the partnerships and collaborations between computing giants and in vitro diagnostic experts. It profiles companies and analyzes the impact this trend will have on future markets.

Related Links:
Kalorama Information



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Specimen Radiography System
TrueView 200 Pro
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The Volition Nu.Q nucleosome assay runs on the IDS i10 automated analyzer platform (Photo courtesy of VolitionRx)

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.